Annals of Epidemiology
Volume 19, Issue 7 , Pages 455-461 , July 2009

Vitamin D and Melanoma

  • Kathleen M. Egan, ScD

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Kathleen M. Egan, ScD, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Dr., MRC 2nd Floor, Tampa, FL 33612. Tel.: (813) 745-6149; fax: (813) 745-6525.

Received 14 May 2007 ,Accepted 6 January 2009.

References 

  1. Lund LP, Timmins GS. Melanoma, long wavelength ultraviolet and sunscreens: controversies and potential resolutions. Pharmacol Ther. 2007;114:198–207Epub 2007 Feb 15
  2. Brannon PM, Yetley EA, Bailey RL, Picciano MF. Overview of the conference “Vitamin D and Health in the 21st Century: an Update”. Am J Clin Nutr. 2008;88:483S–490S.
  3. Oikawa A, Nakayasu M. Stimulation of melanogenesis in cultured melanoma cells by calciferols. FEBS Lett. 1974;42:32–35
  4. Colston K, Colston MJ, Fieldsteel AH, Feldman D. 1,25-dihydroxyvitamin D3 receptors in human epithelial cancer cell lines. Cancer Res. 1982;42:856–859
  5. Frampton RJ, Suva LJ, Eisman JA, Findlay DM, Moore GE, Moseley JM, et al. Presence of 1,25-dihydroxyvitamin D3 receptors in established human cancer cell lines in culture. Cancer Res. 1982;42:1116–1119
  6. Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology. 1981;108:1083–1086
  7. Reichrath J, Rafi L, Rech M, Meineke V, Tilgen W, Seifert M. No evidence for amplification of 25-hydroxyvitamin D-1alpha-OHase (1alpha-OHase) or 1,25-dihydroxyvitamin D-24-OHase (24-OHase) genes in malignant melanoma. J Steroid Biochem Mol Biol. 2004;89-90:163–166
  8. Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma?. Br J Dermatol. 2002;147:197–213
  9. Albert DM, Kumar A, Strugnell SA, Darjatmoko SR, Lokken JM, Lindstrom MJ, et al. Effectiveness of 1alpha-hydroxyvitamin D2 in inhibiting tumor growth in a murine transgenic pigmented ocular tumor model. Arch Ophthalmol. 2004;122:1365–1369
  10. Reichrath J. Vitamin D and the skin: an ancient friend, revisited. Exp Dermatol. 2007;16:618–625
  11. Lehmann B. The vitamin D3 pathway in human skin and its role for regulation of biological processes. Photochem Photobiol. 2005;81:1246–1251
  12. Bikle DD. Vitamin D and the immune system: role in protection against bacterial infection. Curr Opin Nephrol Hypertens. 2008;17:348–352
  13. Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, Soler D, et al. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat Immunol. 2007;8:285–293Epub 2007 Jan 28
  14. De Haes P, Garmyn M, Verstuyf A, De Clercq P, Vandewalle M, Degreef H, et al. 1,25-Dihydroxyvitamin D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage. J Photochem Photobiol B. 2005;78:141–148
  15. Gupta R, Dixon KM, Deo SS, Holliday CJ, Slater M, Halliday GM, et al. Photoprotection by 1,25 dihydroxyvitamin D3 is associated with an increase in p53 and a decrease in nitric oxide products. J Invest Dermatol. 2007;127:707–715Epub 2006 Dec 14
  16. Beissert S, Loser K. Molecular and cellular mechanisms of photocarcinogenesis. Photochem Photobiol. 2008;84:29–34
  17. Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Investig Dermatol Symp Proc. 1996 Apr;1(2):136–142
  18. Agar NS, Halliday GM, Barnetson RS, Ananthaswamy HN, Wheeler M, Jones AM. The basal layer in human squamous tumors harbors more UVA than UVB fingerprint mutations: a role for UVA in human skin carcinogenesis. Proc Natl Acad Sci U S A. 2004;101:4954–4959Epub 2004 Mar 23
  19. Halliday GM, Agar NS, Barnetson RS, Ananthaswamy HN, Jones AM. UV-A fingerprint mutations in human skin cancer. Photochem Photobiol. 2005;81:3–8
  20. Garland FC, White MR, Garland CF, Shaw E, Gorham ED. Occupational sunlight exposure and melanoma in the U.S. Navy. Arch Environ Health. 1990;45:261–267
  21. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer. 1997;73:198–203
  22. Elwood JM, Gallagher RP, Hill GB, Pearson JC. Cutaneous melanoma in relation to intermittent and constant sun exposure—the Western Canada Melanoma Study. Int J Cancer. 1985;35:427–433
  23. Beral V, Robinson N. The relationship of malignant melanoma, basal and squamous skin cancers to indoor and outdoor work. Br J Cancer. 1981;44:886–891
  24. Linet MS, Malker HS, Chow WH, McLaughlin JK, Weiner JA, Stone BJ, et al. Occupational risks for cutaneous melanoma among men in Sweden. J Occup Environ Med. 1995;37:1127–1135
  25. Fears TR, Bird CC, Guerry D, Sagebiel RW, Gail MH, Elder DE, et al. Average midrange ultraviolet radiation flux and time outdoors predict melanoma risk. Cancer Res. 2002;62:3992–3996
  26. Gervin CM, McCulla A, Williams M, Ouhtit A. Dysfunction of p53 in photocarcinogenesis. Front Biosci. 2003;8:s715–s717
  27. Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J Clin Oncol. 2007;25:1606–1620
  28. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95:1878–1890
  29. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–2147
  30. Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res. 2006;16:267–273
  31. Wu J, Rosenbaum E, Begum S, Westra WH. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. Am J Dermatopathol. 2007;29:534–537
  32. Gorham ED, Mohr SB, Garland CF, Chaplin G, Garland FC. Do sunscreens increase risk of melanoma in populations residing at higher latitudes?. Ann Epidemiol. 2007;17:956–963
  33. Diffey B. Sunscreen isn't enough. J Photochem Photobiol B. 2001;64:105–108
  34. Scherschun L, Lim HW. Photoprotection by sunscreens. Am J Clin Dermatol. 2001;2:131–134
  35. Farrerons J, Barnadas M, Rodriguez J, Renau A, Yoldi B, Lopez-Navidad A, et al. Clinically prescribed sunscreen (sun protection factor 15) does not decrease serum vitamin D concentration sufficiently either to induce changes in parathyroid function or in metabolic markers. Br J Dermatol. 1998;139:422–427
  36. Marks R, Foley PA, Jolley D, Knight KR, Harrison J, Thompson SC. The effect of regular sunscreen use on vitamin D levels in an Australian population. Results of a randomized controlled trial. Arch Dermatol. 1995;131:415–421
  37. Matsuoka LY, Wortsman J, Hanifan N, Holick MF. Chronic sunscreen use decreases circulating concentrations of 25-hydroxyvitamin D. A preliminary study. Arch Dermatol. 1988;124:1802–1804
  38. Matsuoka LY, Wortsman J, Hollis BW. Use of topical sunscreen for the evaluation of regional synthesis of vitamin D3. J Am Acad Dermatol. 1990;22:772–775
  39. Gallagher RP, Spinelli JJ, Lee TK. Tanning beds, sunlamps, and risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev. 2005;14:562–566
  40. Veierod MB, Weiderpass E, Thorn M, Hansson J, Lund E, Armstrong B, et al. A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J Natl Cancer Inst. 2003;95:1530–1538
  41. Autier P. Perspectives in melanoma prevention: the case of sunbeds. Eur J Cancer. 2004;40:2367–2376
  42. Gerber B, Mathys P, Moser M, Bressoud D, Braun-Fahrlander C. Ultraviolet emission spectra of sunbeds. Photochem Photobiol. 2002;76:664–668
  43. Lamberg-Allardt C. Vitamin D in foods and as supplements. Prog Biophys Mol Biol. 2006;92:33–38Epub 2006 Feb 28
  44. Weinstock MA, Stampfer MJ, Lew RA, Willett WC, Sober AJ. Case-control study of melanoma and dietary vitamin D: implications for advocacy of sun protection and sunscreen use. J Invest Dermatol. 1992;98:809–811
  45. Millen AE, Tucker MA, Hartge P, Halpern A, Elder DE, Guerry D, et al. Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev. 2004;13:1042–1051
  46. Bain C, Green A, Siskind V, Alexander J, Harvey P. Diet and melanoma. An exploratory case-control study. Ann Epidemiol. 1993;3:235–238
  47. Stryker WS, Stampfer MJ, Stein EA, Kaplan L, Louis TA, Sober A, et al. Diet, plasma levels of beta-carotene and alpha-tocopherol, and risk of malignant melanoma. Am J Epidemiol. 1990;131:597–611
  48. Gallagher RP, Elwood JM, Hill GB. Risk factors for cutaneous malignant melanoma: the Western Canada Melanoma Study. Recent Results Cancer Res. 1986;102:38–55
  49. Hutchinson PE, Osborne JE, Lear JT, Smith AG, Bowers PW, Morris PN, et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res. 2000;6:498–504
  50. Halsall JA, Osborne JE, Potter L, Pringle JH, Hutchinson PE. A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibility and prognosis in malignant melanoma. Br J Cancer. 2004;91:765–770
  51. Han J, Colditz GA, Hunter DJ. Polymorphisms in the MTHFR and VDR genes and skin cancer risk. Carcinogenesis. 2007;28:390–397
  52. Li C, Liu Z, Zhang Z, Strom SS, Gershenwald JE, Prieto VG, et al. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol. 2007;127:276–280
  53. Povey JE, Darakhshan F, Robertson K, Bisset Y, Mekky M, Rees J, et al. DNA repair gene polymorphisms and genetic predisposition to cutaneous melanoma. Carcinogenesis. 2007;28:1087–1093
  54. Santonocito C, Capizzi R, Concolino P, Lavieri MM, Paradisi A, Gentileschi S, et al. Association between cutaneous melanoma, Breslow thickness and vitamin D receptor BsmI polymorphism. Br J Dermatol. 2007;156:277–282
  55. Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol. 2001;177:145–159
  56. Carling T, Rastad J, Akerstrom G, Westin G. Vitamin D receptor (VDR) and parathyroid hormone messenger ribonucleic acid levels correspond to polymorphic VDR alleles in human parathyroid tumors. J Clin Endocrinol Metab. 1998;83:2255–2259
  57. Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, et al. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006;166:1907–1914
  58. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96Epub 2008 Feb 20
  59. Harris SS. Vitamin D and African Americans. J Nutr. 2006;136:1126–1129
  60. Fears TR, Tucker MA. Re: Sun exposure and mortality from melanoma. J Natl Cancer Inst. 2005;97:1789–1790author reply 1791
  61. Heenan PJ, English DR, Holman CD, Armstrong BK. Survival among patients with clinical stage I cutaneous malignant melanoma diagnosed in Western Australia in 1975/1976 and 1980/1981. Cancer. 1991;68:2079–2087
  62. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer. 1996;78:427–432
  63. Berwick M, Armstrong BK, Ben-Porat L, Fine J, Kricker A, Eberle C, et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst. 2005;97:195–199
  64. Larsen TE, Grude TH. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. 6. The relation of dermal solar elastosis to sex, age and survival of the patient and to localization, histological type and level of invasion of the tumour. Acta Pathol Microbiol Scand [A]. 1979;87A:361–366
  65. Vollmer RT. Solar elastosis in cutaneous melanoma. Am J Clin Pathol. 2007;128:260–264
  66. Dicker TJ, Kavanagh GM, Herd RM, Ahmad T, McLaren KM, Chetty U, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol. 1999;140:249–254
  67. Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER)program. Arch Dermatol. 2008;144:515–521
  68. Nürnberg B, Schadendorf D, Gärtner B, Pföhler C, Herrmann W, Tilgen W, et al. Progression of malignant melanoma is associated with reduced 25-hydroxyvitamin D serum levels. Exp Dermatol. 2008;17:627
  69. Nagpal S, Lu J, Boehm MF. Vitamin D analogs: mechanism of action and therapeutic applications. Curr Med Chem. 2001;8:1661–1679Review
  70. Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP, et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr. 2007;85:649–650No abstract available. Erratum in: Am J Clin Nutr. 2007;86:809
  71. Diffey BL. Sunscreens and melanoma: the future looks bright. Br J Dermatol. 2005;153:378–381

PII: S1047-2797(09)00016-7

doi: 10.1016/j.annepidem.2009.01.005

Annals of Epidemiology
Volume 19, Issue 7 , Pages 455-461 , July 2009

Article Tools